Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
47
MIST Quote, Financials, Valuation and Earnings
Last price:
$2.64
Seasonality move
:
-15.55%
Day range:
$2.52 - $2.69
52-week range:
$0.63 - $2.77
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
10.88x
Volume:
3.4M
Avg. volume:
2.7M
1-year change:
40.86%
Market cap:
$223.1M
Revenue:
--
EPS (TTM):
-$0.86
Analysts' Opinion
-
Consensus RatingMilestone Pharmaceuticals, Inc. has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $3.75, Milestone Pharmaceuticals, Inc. has an estimated upside of 43.13% from its current price of $2.62.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $2.62.
Fair Value
-
According to the consensus of 4 analysts, Milestone Pharmaceuticals, Inc. has 43.13% upside to fair value with a price target of $3.75 per share.
MIST vs. S&P 500
-
Over the past 5 trading days, Milestone Pharmaceuticals, Inc. has overperformed the S&P 500 by 6.06% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Milestone Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Milestone Pharmaceuticals, Inc. revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Milestone Pharmaceuticals, Inc. reported revenues of --.
Earnings Growth
-
Milestone Pharmaceuticals, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Milestone Pharmaceuticals, Inc. reported earnings per share of -$0.12.
Enterprise value:
197.8M
EV / Invested capital:
2.54x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.04x
EV / Free cash flow:
-4.58x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$647K
Return On Assets:
-81.65%
Net Income Margin (TTM):
--
Return On Equity:
-858.37%
Return On Invested Capital:
-93.03%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $4.5M | -- | -- | -- | -- | |
| Gross Profit | $4M | -$611K | -$647K | -$25K | -$25K | |
| Operating Income | -$61.4M | -$43.8M | -$57.5M | -$9.7M | -$11.9M | |
| EBITDA | -$61M | -$43.2M | -$56.9M | -$9.7M | -$11.9M | |
| Diluted EPS | -$1.38 | -$0.90 | -$0.86 | -$0.14 | -$0.12 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $132.8M | $82.9M | $84.8M | $81M | $86.7M | |
| Total Assets | $133.8M | $85.8M | $87.1M | $82.7M | $87.8M | |
| Current Liabilities | $5.8M | $6.5M | $8.1M | $5.3M | $10.5M | |
| Total Liabilities | $6.4M | $8.6M | $58.6M | $58.7M | $67.2M | |
| Total Equity | $127.4M | $77.2M | $28.5M | $24M | $20.5M | |
| Total Debt | $766K | $2.1M | $50.5M | $53.4M | $56.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$48.2M | -$31.1M | -$43.2M | -$7M | -$9.8M | |
| Cash From Investing | -$24.3M | $2.7M | $27.8M | $6.4M | -$35.6M | |
| Cash From Financing | $48.1M | $31.3M | $49.3M | $175.6K | $49.7M | |
| Free Cash Flow | -$48.4M | -$31.2M | -$43.2M | -$7M | -$9.8M | |
MIST
Sector
Market Cap
$223.1M
$28.4M
Price % of 52-Week High
94.59%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-29.43%
-1.32%
1-Year Price Total Return
40.86%
-22.19%
Beta (5-Year)
0.408
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$2.56
200-day SMA
Buy
Level
$1.72
Bollinger Bands (100)
Buy
Level
1.6 - 2.18
Chaikin Money Flow
Buy
Level
7.4M
20-day SMA
Buy
Level
$2.23
Relative Strength Index (RSI14)
Buy
Level
70.97
ADX Line
Buy
Level
41.75
Williams %R
Sell
Level
-16.3043
50-day SMA
Buy
Level
$2.08
MACD (12, 26)
Buy
Level
0.25
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
10M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.4096)
Sell
CA Score
(Annual)
Level (-4.3842)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (5.1979)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.
Stock Forecast FAQ
In the current month, MIST has received 2 Buy ratings 2 Hold ratings, and 0 Sell ratings. The MIST average analyst price target in the past 3 months is $3.75.
-
Where Will Milestone Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Milestone Pharmaceuticals, Inc. share price will rise to $3.75 per share over the next 12 months.
-
What Do Analysts Say About Milestone Pharmaceuticals, Inc.?
Analysts are divided on their view about Milestone Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Milestone Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Milestone Pharmaceuticals, Inc.'s Price Target?
The price target for Milestone Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $3.75 according to 4 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is MIST A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Milestone Pharmaceuticals, Inc. is a Leans Bullish. 2 of 4 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of MIST?
You can purchase shares of Milestone Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Milestone Pharmaceuticals, Inc. shares.
-
What Is The Milestone Pharmaceuticals, Inc. Share Price Today?
Milestone Pharmaceuticals, Inc. was last trading at $2.64 per share. This represents the most recent stock quote for Milestone Pharmaceuticals, Inc.. Yesterday, Milestone Pharmaceuticals, Inc. closed at $2.62 per share.
-
How To Buy Milestone Pharmaceuticals, Inc. Stock Online?
In order to purchase Milestone Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get MIST Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MIST
Sector
P/E ratio
--
23.66x
PEG ratio
-0.04x
-0.01x
P/B ratio
10.88x
1.84x
Price / LTM sales
--
1.60x
Growth Metrics
MIST
Sector
Revenue growth
--
4.85%
Earnings growth
13.39%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.17
-$0.20
Profitability
MIST
Sector
Profitability FY 2024
-$646K
$3.6M
Return on invested capital
-93.03%
-30.98%
Return on assets
-81.65%
-27.62%
Return on equity
-858.37%
-36.69%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
12
Estimated Next Earnings Date
Feb
11
Balance Sheet
MIST
Sector
Total cash
$82.6M
$27.2M
Short term investments
$44.4M
$25.7M
Total assets
$75.5M
$79.9M
Long term debt
$56.7M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
65
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
